BioWorld

March 17, 2003

View Archived Issues

Trimeris, Roche's First-In-Class HIV Drug, Fuzeon, Approved

The FDA cleared the accelerated approval application for Fuzeon, a first-in-class fusion inhibitor for HIV-1 developed by Trimeris Inc., and partner F. Hoffmann-La Roche Ltd. (BioWorld Today) Read More

The Medicines Co. Offering Gets $85.75M For Late-Stage Work

Read More

Activation Of Brain-Specific Genes Adds Data To Fragile X Syndrome, A Main Form Of Mental Retardation

Read More

Inspire Increases Share Amount, Raises $67.5M For Eye Products

Read More

Other News To Note

Read More